Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease

doi:10.4254/wjh.v17.i11.110698

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

(49)

(48)

(0)

(1)

(769)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Hepatol. Nov 27, 2025; 17(11): 110698
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110698

Table 3 Non-invasive test, n (%)

Cytokeratin 18 fragment (high: > 260 U/L)		Normal	High	P value
FIB-4	n	96	29	0.18622
	Median	1.846233758	2.214285714
	Q1 (25%)	1.335421229	1.350050748
	Q3 (75%)	3.034660172	4.838339769
FIB-4 < 1.3	Normal	20 (20.8)	7 (24.1)	0.70470
FIB-4 < 1.3	< 1.3	76 (79.2)	22 (75.9)	0.70470
FIB-4 < 2.67	Normal	66 (68.8)	15 (51.7)	0.09249
FIB-4 < 2.67	< 2.57	30 (31.3)	14 (48.3)	0.09249
SAFE score	n	96	29	0.00038
	Median	106.392705050	180.732578700
	Q1 (25%)	37.891624800	129.469594725
	Q3 (75%)	183.716030000	286.774864650
SAFE low-risk, moderate-risk, and high-risk	Low (< 0)	16 (16.7)	0 (0.0)	0.00696
	Mod (0-100)	30 (31.3)	5 (17.2)
	High (> 100)	50 (52.1)	24 (82.8)
LS	n	86	29	0.05020
	Median	6.1	7.2
	Q1 (25%)	4.1	5.4
	Q3 (75%)	9.3	12.7
LS < 8	LS > 8	32 (37.2)	14 (48.3)	0.29281
LS < 8	LS < 8	54 (62.8)	15 (51.7)	0.29281
LS < 10	LS > 10	19 (22.1)	10 (34.5)	0.18396
LS < 10	LS < 10	67 (77.9)	19 (65.5)	0.18396
Controlled attenuation parameter (dB/m)	n	86	29	0.03146
	Median	283.0	313.0
	Q1 (25%)	250.0	261.3
	Q3 (75%)	318.0	350.3
FAST	n	86	29	< 0.00001
	Median	0.1	0.4
	Q1 (25%)	0.1	0.3
	Q3 (75%)	0.3	0.6
FAST < 0.35	Low	66 (76.7)	12 (41.4)	0.00042
FAST < 0.35	High	20 (23.3)	17 (58.6)	0.00042
Model for end-stage liver disease	n	95	29	0.16863
	Median	7.0	7.0
	Q1 (25%)	6.0	7.0
	Q3 (75%)	8.0	9.0
Albumin bilirubin score	n	96	29	0.96034
	Median	−2.9491	−2.9051
	Q1 (25%)	−3.1863	−3.1601
	Q3 (75%)	−2.6099	−2.7345
Child–Pugh score	n	96	29	0.40759
	Median	5	5
	Q1 (25%)	5	5
	Q3 (75%)	5	5

FAST: FibroScan-aspartate aminotransferase; FIB-4: Fibrosis-4 index; LS: Liver stiffness; Q1: Quartile 1 (25%); Q3: Quartile 3 (75%); SAFE: Steatosis-associated fibrosis estimator.

Full Size Table

Citation: Ichikawa T, Miuma S, Yamashima M, Yamamichi S, Koike M, Nakano Y, Yajima H, Miyazaki O, Ikeda T, Okamura T, Komatsu N, Yoshino M, Miyaaki H. Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease. World J Hepatol 2025; 17(11): 110698
URL: https://www.wjgnet.com/1948-5182/full/v17/i11/110698.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i11.110698

Ichikawa T, Miuma S, Yamashima M, Yamamichi S, Koike M, Nakano Y, Yajima H, Miyazaki O, Ikeda T, Okamura T, Komatsu N, Yoshino M, Miyaaki H. Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease. World J Hepatol 2025; 17(11): 110698 [PMID: 41368122 DOI: 10.4254/wjh.v17.i11.110698]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.